Clinical trials: Immunodeficiency
Hiv
'Activity Pacing' in PLWH With Fatigue Symptoms.
Physical activity helps to improve health and prevent chronic diseases. However, the fatigue usually hampers the training and execution of physical exercises, especially in people with chronic fatigue syndromes (CFCs), such as…
- Trial name
- ActiPacMAN (NCT05194059)
- Testing
- Home-based physical activity
- Where
- Italy
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Scientific Institute San Raffaele
HIV Infections, Tuberculosis Infection
European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol
Across Europe and worldwide, there are many studies following groups (cohorts) of children living with human immunodeficiency virus (HIV) and other infections over time, to monitor their long-term health.
- Conditions
- HIV Infections, Tuberculosis Infection, Hepatitis C, Covid19
- Trial name
- EPPICC (NCT04677842)
- Testing
- ART Therapy
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- PENTA Foundation
Human Immunodeficiency Virus
Peers Plus Mobile App for Treatment in HIV
This study called "Peers plus mobile App for Treatment in HIV (PATH)" is a two-arm randomized controlled trial (RCT) evaluating the efficacy of an intervention that combines peer navigation and mobile health (mHealth) technology…
- Trial name
- PATH (NCT05427318)
- Testing
- PATH
- Where
- United States
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- San Diego State University
HIV Infections
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
- Trial name
- NCT06741397
- Testing
- CAB LA, New formulation of CAB LA
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Multi Drug Resistant Tuberculosis, HIV Infections
An Adaptive Randomized Controlled Trial
This is a prospective, adaptive, randomized controlled trial comparing the effectiveness of 4 intervention arms on a combined endpoint in adults with confirmed MDR-TB HIV initiating Bedaquiline-containing MDR-TB treatment…
- Trial name
- ADAP-TIV (NCT05633056)
- Testing
- Adherence support intevention
- Where
- South Africa
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hiv
Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy
Adherence to antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) are critical to the success of HIV treatment and therapeutic prevention.
- Trial name
- TARGET (NCT03012607)
- Testing
- Truvada
- Where
- Thailand
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Washington
Progressive Multifocal Leukoencephalopathy
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Background: Progressive multifocal leukoencephalopathy (PML) is a severe viral infection of the brain. It is caused by JC virus.
- Trial name
- NCT01730131
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Cytomegalovirus Infections, Cytomegalovirus Retinitis
A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection
The purpose of this study is to understand how changes in the immune system of HIV-infected patients affect their risk for 3 serious infections: Pneumocystis carinii pneumonia (PCP), cytomegalovirus (CMV) retinitis, or CMV organ…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, Pneumonia, Pneumocystis Carinii, HIV Infections
- Trial name
- NCT00005572
- Where
- 16 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Treponema Pallidum, Treponema Pallidum Infection
This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.
This study will evaluate the clinical performance of two investigational diagnostic kits developed by ALPCO: the Syphilis-T CLIA Kit and the Syphilis-NT CLIA Kit.
- Conditions
- Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum
- Trial name
- NCT07089836
- Testing
- ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
- Where
- 6 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
HIV Infections
A Study to Explore the Association Between Blood Pressure, HIV and Antiretroviral Therapy
The purpose of this study is to explore the association between blood pressure, HIV and/or its treatment in a cross sectional observational study.
- Trial name
- NCT00131807
- Testing
- Blood Pressure Measurement, Questionnaire
- Where
- United Kingdom
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HIV Infections
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults
This is a phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 trimer Vaccine, Adjuvanted, in up to 48 healthy HIV-uninfected adult volunteers.
- Trial name
- NCT04224701
- Testing
- BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Tuberculosis, HIV/AIDS
TB Reduction Through ART and TB Screening Project
Tuberculosis (TB) has overtaken HIV as the leading infectious cause of death worldwide and requires a major policy shift for it to be controlled in line with the WHO Stop-TB goal to "end TB".
- Trial name
- TREATS (NCT03739736)
- Testing
- Combination of TB/HIV prevention activities (arm A), Combination of TB/HIV prevention activities (arm B), Standard of care (arm C)
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
HIV/AIDS, STI
MAKASI Intervention for African and Caribbean Migrants' Empowerment in Sexual Health in Paris Greater Area
Background. Immigrants from Sub-Saharan Africa are the second group most affected by HIV in France. Part of these HIV infections occurred after arrival in France, in relation to social hardships.
- Trial name
- MAKASI (NCT04468724)
- Testing
- MAKASI
- Where
- France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
The Safety and Immunogenicity of a Potential HIV Vaccine
The potential HIV vaccine has two components: a protein immunogen based on the coat protein of HIV; and an adjuvant which enhances the vaccinee's response to the immunogen.
- Trial name
- NCT01966900
- Testing
- CN54gp140 mixed with GLA-AF
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HIV Infections
Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women
Topical microbicides, substances that kill microbes, are being studied to prevent sexual transmission of HIV and other disease-causing agents.
- Trial name
- NCT00594373
- Testing
- Tenofovir gel
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, Infant Morbidity
Assessing the Feasibility, Acceptability and Effects Of HIV Birth Testing In Maternity Settings In Zimbabwe
This study aims to assess the feasibility and, acceptability and effects of implementing HIV testing at birth testing using point-of-care (POC) HIV nucleic acid testing (NAT) in maternity settings.
- Conditions
- HIV/AIDS, Infant Morbidity, Perinatal HIV Infection, HIV Infections
- Trial name
- NCT04206241
- Testing
- Point of care early infant diagnosis (POC EID)
- Where
- 10 sites in Zimbabwe
- Volunteers
- 278,833 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Nutrient Deficiency, Age-Related Immunodeficiency
Milk Biofortification Promotes Health Benefits in Institutionalized Elderly
The project aims to study the effects of inclusion of sunflower oil, vitamin E and selenium in the diet of dairy cows on milk composition and the influence of modified milk on nutrition and health of elderly.
- Conditions
- Nutrient Deficiency, Age-Related Immunodeficiency, Vitamin E Deficiency, Selenium Deficiency
- Trial name
- NCT02980094
- Testing
- Milk Antioxidant group(A), Milk Oil group(O), Milk Antioxidant and oil(AO)
- Where
- Brazil
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Eduardo Ferriolli
Infection, Human Immunodeficiency Virus
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT02738931
- Testing
- Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
The Raltegravir and Ribavirin Pharmacokinetics (PK) Study
The purpose of this study is to look at levels of both a new anti-HIV drug called raltegravir and an existing anti-hepatitis C drug called ribavirin to see if they affect the blood levels of each other when given separately and…
- Trial name
- NCT00982553
- Testing
- Ribavirin, Raltegravir
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HCV Infection, HIV Infections
Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid
Data on the prevalence of hepatitis C virus (HCV) for other vulnerable groups in Madrid, such as homeless persons and migrants, are scarce, and it is now necessary to implement intervention and elimination plans.
- Conditions
- HCV Infection, HIV Infections, Drug Use, HBV (Hepatitis B Virus)
- Trial name
- (UMC) (NCT04062253)
- Testing
- HCV rapid test
- Where
- Spain
- Volunteers
- 2,001 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Infanta Leonor